GlassScriptPhysician profile
Benjamin David Williamson
NPI 1871047787
$2,925.69
in general payments reported to CMS, 2019-2025
29 companies · $785 in 2025
The $785 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $79.08 · 2022: $480 · 2023: $961 · 2024: $620 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,366.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $726.46 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $477.57 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $308.67 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $235.20 | 2022-2025 | |
| Pfizer INC. | $174.87 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $173.02 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $95.14 | 2022-2025 | |
| Exact Sciences Corporation | $72.43 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.49 | 2023 | Xifaxan |
| Neurocrine Biosciences, INC. | $58.61 | 2022-2023 | Ingrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.86 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $48.19 | 2022-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $45.76 | 2025 | Lagevrio |
| Takeda Pharmaceuticals U.S.A., INC. | $44.61 | 2022-2023 | Trintellix |
| Sanofi-Aventis U.S. LLC | $38.71 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $36.10 | 2023 | Freestyle Libre 2, Octrode |
| Novartis Pharmaceuticals Corporation | $31.12 | 2021-2023 | |
| Dexcom, INC. | $30.29 | 2024-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $29.43 | 2023-2025 | Voquezna |
| Medline Industries LP | $24.01 | 2024 | Medline |
| Otsuka America Pharmaceutical, INC. | $23.35 | 2024 | Rexulti |
| Lundbeck LLC | $20.54 | 2023 | Rexulti |
| Amarin Pharma, INC. | $19.08 | 2021 | |
| Boston Scientific Corporation | $18.71 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.40 | 2024 | Gvoke Hypopen |
| Nestle Healthcare Nutrition INC. | $15.54 | 2022 | |
| Amgen INC. | $13.96 | 2023 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $13.91 | 2022 | |
| Sanofi Pasteur INC. | $12.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Williamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.